BRCA2 and neoplasm: Deletion patterns can most accurately identify defects of BRCA2 and PALB2, also confirmed in tumor genomes; therefore, a high proportion of deletions with microhomologies may be a good predictor of treatment with PARP inhibitors, cisplatin or carboplatin.